ENDRA files FDA De Novo for TAEUS liver system; Q2 loss $2.6M, cash $4.8M

ENDRA Life Sciences Inc.

Submitted De Novo request to FDA for TAEUS liver fat assessment system; clinical data showed 90% sensitivity and correlation r=0.78 vs MRI-PDFF.
Q2 2023 net loss $2.6M ($0.43/share) vs $3.6M ($1.17) in Q2 2022; operating expenses fell to $3.0M from $3.6M.
Cash and equivalents $4.8M at June 30; $4.7M net raised in May 2023 public offering to extend runway through key 2023 milestones.
IP portfolio expanded to 64 issued patents globally; four new patents issued in Q2 (one US, three China).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the quarter ended June 30, 2023 results: net income Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, EPS $0.43 per share.

Period: the quarter ended June 30, 2023
Net income: Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share
EPS: $0.43 per share
Result: reported results

Exact text from the filing

On August 14, 2023, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-010765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.